EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

IL‐8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR‐146a mediated mechanism

Brianna L Hill, Alyssa N Calder, Joseph P Flemming, Yiyang Guo, Sydney L Gilmore, Melissa A Trofa, Sean K Daniels, Torbjoern N Nielsen, Laura K Gleason, Zoya Antysheva, Ksenia Demina, Nikita Kotlov and 13 more

Molecular Carcinogenesis · 2023

DOI: 10.1002/mc.23587 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2023. Written by Brianna L Hill and 24 co-authors. Institution: Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Papillomavirus Infections, MicroRNAs, Head and Neck Neoplasms, Extracellular Vesicles. Cited 8 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIAMS NIH HHS, NCI NIH HHS, NIAAA NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Therapy using anti‐PD‐1 immune checkpoint inhibitors (ICI) has revolutionized the treatment of many cancers including head and neck squamous cell carcinomas (HNSCC), but only a fraction of patients respond. To better understand the molecular mechanisms driving resistance, we performed extensive analysis of plasma and tumor tissues before and after a 4‐week neoadjuvant trial in which HNSCC patients were treated with the anti‐PD‐1 inhibitor, nivolumab. Luminex cytokine analysis of patient plasma demonstrated that HPV pos nonresponders displayed high levels of the proinflammatory chemokine, interleukin‐8 (IL‐8), which decreased after ICI treatment, but remained higher than responders. miRNAseq analysis of tetraspanin‐enriched small extracellular vesicles (sEV) purified from plasma of HPV pos nonresponders demonstrated significantly lower levels of seven miRNAs that target IL‐8 including miR‐146a. Levels of the pro‐survival oncoprotein Dsg2, which has been to down‐regulate miR‐146a, are elevated with HPV pos tumors displaying higher levels than HPV neg tumors. Dsg2 levels decrease significantly following ICI in responders but not in nonresponders. In cultured HPV pos cells, restoration of miR‐146a by forced expression or treatment with miR‐146a‐loaded sEV, reduced IL‐8 level, blocked cell cycle progression, and promoted cell death. These findings identify Dsg2, miR‐146a, and IL‐8 as potential biomarkers for ICI response and suggest that the Dsg2/miR‐146a/IL‐8 signaling axis negatively impacts ICI treatment outcomes and could be targeted to improve ICI responsiveness in HPV pos HNSCC patients.

Subjects

MeSH terms (MEDLINE)

Papillomavirus InfectionsMicroRNAsHead and Neck NeoplasmsExtracellular VesiclesHumansSquamous Cell Carcinoma of Head and NeckInterleukin-8NivolumabNeoadjuvant Therapy

Author keywords

chemokinedesmogleinextracellular vesicleimmune checkpoint inhibitormicroRNA

Substances

Interleukin-8NivolumabMicroRNAs

Authors and institutions

  • Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
  • Sidney Kimmel Medical School, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • John A. Burns School of Medicine, University of Hawai'i at Mānoa Honolulu, Honolulu, USA.
  • BostonGene Corporation, Waltham, Massachusetts, USA.

Funding

  • NIAMS NIH HHS
  • NCI NIH HHS
  • NIAAA NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Institute on Alcohol Abuse and Alcoholism
  • Bristol-Myers Squibb

Cite

APA

Hill, B. L., Calder, A. N., Flemming, J. P., Guo, Y., Gilmore, S. L., Trofa, M. A., Daniels, S. K., Nielsen, T. N., Gleason, L. K., Antysheva, Z., Demina, K., Kotlov, N., Davitt, C. J. H., Cognetti, D. M., Prendergast, G. C., Snook, A. E., Johnson, J. M., Kumar, G., Linnenbach, A. J., …, & Mahoney, M. G. (2023). IL‐8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR‐146a mediated mechanism. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23587

Vancouver

Hill BL, Calder AN, Flemming JP, Guo Y, Gilmore SL, Trofa MA, et al. IL‐8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR‐146a mediated mechanism. Molecular Carcinogenesis. 2023. doi:10.1002/mc.23587

BibTeX
@article{Hill2023,
  author = {Hill, Brianna L and Calder, Alyssa N and Flemming, Joseph P and Guo, Yiyang and Gilmore, Sydney L and Trofa, Melissa A and Daniels, Sean K and Nielsen, Torbjoern N and Gleason, Laura K and Antysheva, Zoya and Demina, Ksenia and Kotlov, Nikita and Davitt, Christopher J H and Cognetti, David M and Prendergast, George C and Snook, Adam E and Johnson, Jennifer M and Kumar, Gaurav and Linnenbach, Alban J and Martinez-Outschoorn, Ubaldo and South, Andrew P and Curry, Joseph M and Harshyne, Larry A and Luginbuhl, Adam J and Mahoney, Mỹ G},
  title = {IL‐8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR‐146a mediated mechanism},
  journal = {Molecular Carcinogenesis},
  year = {2023},
  doi = {10.1002/mc.23587}
}
Start for free →